Autres langues Lixte Biotechnology Holdings, Inc.

Actions

LIXT

US5393193017

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 28/06/2024			Varia. 5j.	Varia. 1 janv.
2,37 ^USD	0,00%		-6,69%	+0,85%

14/06	Lixte Biotechnology Holdings, Inc. collabore avec Roche et l'Institut néerlandais du cancer dans le cadre d'un nouvel essai clinique sur le cancer du côlon	CI
06/06	Lixte Biotechnology Holdings, Inc. Les résultats des rapports démontrent que le composé clinique principal de LIXTE, LB-100, augmente la reconnaissance des cellules cancéreuses du côlon par le système immunitaire	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial	14/06
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial	14/06
Lixte Biotechnology Holdings, Inc. to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial	14/06
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System	06/06
Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System	06/06
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer	03/06
LIXTE Biotechnology Holdings, Inc. Announces Executive Changes	03/06
LIXTE Biotechnology Holdings Provides Update on Recent Activities	20/05
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”	08/05
Lixte Biotechnology : Investor Presentation - April 2024	30/04
Lixte Biotechnology Files Up to $50 Million Mixed Shelf	23/04
Sector Update: Health Care Stocks Advance Late Afternoon	27/03
Top Midday Gainers	27/03
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	27/03
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES	27/03
Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal	27/03
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	21/03
LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	21/03
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lixte Biotechnology Holdings, Inc.

Actions

LIXT

US5393193017

Autres langues

Filtres